Home health remedies In last-minute deal, Allergan forks over a hefty $300M to settle pay-for-delay...

In last-minute deal, Allergan forks over a hefty $300M to settle pay-for-delay dispute

22
0
SHARE

With AbbVie and Allergan almost ready to wrap up their $63 billion megamerger, both drugmakers are looking to clear any outstanding accounts before the deal closes. And Allergan just agreed to fork over $300 million to resolve one of them.

On the eve of a Monday trial, the company agreed to settle pay-for-delay claims against two of its businesses—Warner Chilcott and Watson Pharmaceuticals. For $300 million and no admission of wrongdoing, Allergan avoids a public trial and a potentially protracted legal wrangle.

Filed by purchasers of Loestrin 24 Fe and Minastrin 24 Fe, the antitrust suits claimed Warner paid off Watson and another generics maker, Lupin Pharmaceuticals, to delay launching cheaper copycats of those two contraceptive pills.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Warner Chilcott also allegedly used a false patent as a basis for “sham lawsuits” against generic manufacturers of Loestrin 24 and switched the market from Loestrin to Minastrin––”a nearly identical product,” according to the lawsuit––in an effort to get doctors to prescribe the newer drug. 

In May, Lupin agreed to settle its end of the suit, reaching a $1 million deal with the plaintiffs to bow out.

RELATED: Warner Chilcott’s marketing probe snared a doctor, and now she could go to prison

Source link